Interaction of diclofenac and ketoprofen with cardioactive drugs in rats

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 34, Issue 1, 2009, Pages 11-17

  Jakovljevic, V ^a   Sabo, A ^a   Tomic Z ^a   Milijasevic B ^a   Popovic, Maria ^b   Vasovic, V ^a   Raskovic A ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Cardiosensitivity; Diclofenac; Ketoprofen

Indexed keywords

ADRENALIN; DICLOFENAC; ISOPAMIL; KETONAL; KETOPROFEN; LIDOCAINE; NACLOFEN; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CARDIOTOXICITY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; FEMALE; INFUSION PUMP; MALE; MORNING DOSAGE; NONHUMAN; POTASSIUM BLOOD LEVEL; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; WISTAR RAT;

EID: 65649104734     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191378     Document Type: Article

References (46)

1. McGettigan P., Henry D. (2006): Cardiovascular risik and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxigenase 2. JAMA, 296, 1633-1634.
2. Ray W.A., Stein C.M., Hall K. (2002): Daugherty J.R., Griffin M.R. Non steroidal anti-inflammatory drugs and risk of serious coronary heart disease; an observational cohort. Lancet, 359, 118-123.
3. Andersohn F. (2006): Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation, 113, 1950-1957.
4. Motola D., Vaccheri A., Silvani M.C., Poluzzi E., Bottoni A., De Ponti F., Montanaro N. (2004): Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur. J. Clin. Pharmacol., 60, 731-738.
5. Jick H., Kaye J.A., Russmann S., Jick S.S (2006): Nonsteroidal antiimflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy, 26, 1379-1387.
6. EMEA press release on non-selective NSAIDS. August 2nd, 2005, http://www.emea.eu.int/pdfs/human/press/pr/24732305en.pdf Accessed 23 August 2006.
7. Arun P.R., Azeez P.A. (2004): Vulture population decline, diclofenac and avian gout. Curr. Sci., 87, 565-568.
8. Singh G., Wu O., Ranghorne P., Madhok R. (2006): Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res. Ther., 8, 153-158.
9. Jakovljevic V., Stanulovic M., Sabo A., Popovic M.(1989): Effect of chronic consumption of caffeine on the autonomous system of isolated rat heart. Yugoslav. Physiol. Pharmacol. Acta, 25, 51-53.
10. Jakovljevic V., Sabo A., Popovic M., Stanulovic M. (1990): Interaction between methalxantine and cardioactive drugs. (Abstract). Eur. J. Pharmacol., 183.
11. Vasovic V., Vukmirovic S., Poša M., Mikov M., Raškovic A., Jakovljevic V. (2006): Effect of rat pretreatment with aqueous solution of stevioside and bile acids on the action of certain cardioactive drugs. Eur. J. Drug Metabol. Pharmacokinet., 31, 311-314.
12. Turner R.A.: Screening Methods in Pharmacology, Academic Press, New York and London, 1965.
13. Owen S.G., Michael S.R., William T.F. (1987): Rapid High-performance liquid chromatographic assay for the simultaneus analysis of non-steroidal antiinflamatory drugs in plasma. J. Chromatogr., 416, 293-302.
14. USP. The United States Pharmacopeia. The national formulary. USP 26th revision (January 1, 2003). NF 21st ed (January 1, 2003). Rockville, MD: The United States Pharmacopoeia Convention, Inc., 2002.
15. Clasco R.K., Ed.: USP DI Drug information for the Health Care P professional. Thomson MICROMEDEX, Inc 2003 P. IV/317
16. Johnston S.A., Fox S.M. (1997): Mechanism of action of anti-inflammatory medications used for the treatment of osteoarthritis. J. Am. Veterin. Med. Assoc, 210, 1486-1492.
17. Oaks J.L., Gilbert M., Virani M.Z., Watson R.T., Meteyer C.U., Rideout B.A., Shivaprasad H.L., Ahmed S., Chaudhry M.J., Arshad M., Mahmood S., Ali A., Khan A.A (2004): Diclofenac residues as the cause of vulture population decline in Pakistan. Nature, 427, 630-633.
18. Noory T., Jarrar B.M. (2006): Histochemical Alterations in the Spleen of Rabbits Induced by Diclofenac Sodium (Voltaren). Science, 19, 21-29.
19. Masubuchi Y., Nakayama S., Horie T. (2002): Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology, 35, 544-551.
20. Hunter R.P., Isaza R., Koch D.E. (2003): Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus). Am. J. Veterin. Res., 64, 109-114.
21. Ishizaki T., Sasaki T., Suganuma T., Horai Y., Chiba K., Watanabe M., Asuke W., Hoshi H. (1980): Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral. Eur. J. Clin. Pharmacol., 18, 407-414.
22. Aberg G., Ciofalo V.B., Pendleton R.G., et al. (1995): Inversion of (R)- to (S)-ketoprofen in eight animal species. Chirality, 7, 383-387.
23. Lees P., Taylor P.M., Landoni F.M., Arifah A.K., Waters C. (2003): Ketoprofen in the Cat. Pharmacodyn. Chiral Pharmacokinet. Veterin. J. 165, 21-35.
24. McGettigan P., Henry D. (2006): Cardiovascular risik and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxigenase 2. JAMA, 296, 1633-1634.
25. Ray W.A., Stein C.M., Hall K. (2002): Daugherty J.R., Griffin M.R. Non steroidal anti-inflammatory drugs and risk of serious coronary heart disease; an observational cohort. Lancet, 359, 118-123.
26. Andersohn F. (2006): Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation, 113, 1950-1957.
27. Motola D., Vaccheri A., Silvani M.C., Poluzzi E., Bottoni A., De Ponti F., Montanaro N. (2004): Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur. J. Clin. Pharmacol., 60, 731-738.
28. Jick H., Kaye J.A., Russmann S., Jick S.S (2006): Nonsteroidal antiimflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy, 26, 1379-1387.
29. EMEA press release on non-selective NSAIDS. August 2nd, 2005) http://www.emea.eu.int/pdfs/human/press/pr/24732305en.pdf Accessed 23 August 2006.
30. Arun P.R., Azeez P.A. (2004): Vulture population decline, diclofenac and avian gout. Curr. Sci., 87, 565-568.
31. Singh G., Wu O., Ranghorne P., Madhok R. (2006) Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res. Ther., 8, 153-158.
32. Jakovljevic V., Stanulovic M., Sabo A., Popovic M.(1989): Effect of chronic consumption of caffeine on the autonomous system of isolated rat heart. Yugoslav. Physiol. Pharmacol. Acta, 25, 51-53.
33. Jakovljevic V., Sabo A., Popovic M., Stanulovic M. (1990): Interaction between methalxantine and cardioactive drugs. (Abstract). Eur. J. Pharmacol., 183.
34. Vasovic V., Vukmirovic S., Poša M., Mikov M., Raškovic A., Jakovljevic V. (2006): Effect of rat pretreatment with aqueous solution of stevioside and bile acids on the action of certain cardioactive drugs. Eur. J. Drug Metabol. Pharmacokinet., 31, 311-314.
35. Turner R.A.: Screening Methods in Pharmacology, Academic Press, New York and London, 1965.
36. Owen S.G., Michael S.R., William T.F. (1987): Rapid High-performance liquid chromatographic assay for the simultaneus analysis of non-steroidal antiinflamatory drugs in plasma. J. Chromatogr., 416, 293-302.
37. USP. The United States Pharmacopeia. The national formulary. USP 26th revision (January 1, 2003). NF 21st ed (January 1, 2003). Rockville, MD: The United States Pharmacopoeia Convention, Inc., 2002.
38. Clasco R.K., Ed.: USP DI Drug information for the Health Care P professional. Thomson MICROMEDEX, Inc 2003 P. IV/317
39. Johnston S.A., Fox S.M. (1997): Mechanism of action of anti-inflammatory medications used for the treatment of osteoarthritis. J. Am. Veterin. Med. Assoc, 210, 1486-1492.
40. Oaks J.L., Gilbert M., Virani M.Z., Watson R.T., Meteyer C.U., Rideout B.A., Shivaprasad H.L., Ahmed S., Chaudhry M.J., Arshad M., Mahmood S., Ali A., Khan A.A (2004): Diclofenac residues as the cause of vulture population decline in Pakistan. Nature, 427, 630-633.
41. Noory T., Jarrar B.M.(2006): Histochemical Alterations in the Spleen of Rabbits Induced by Diclofenac Sodium (Voltaren). Science, 19, 21-29.
42. Masubuchi Y., Nakayama S., Horie T. (2002): Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology, 35, 544-551.
43. Hunter R.P., Isaza, R., Koch D. E. (2003): Oral bioavailability and pharmacokinetic characteristics of ketoprofen enantiomers after oral and intravenous administration in Asian elephants (Elephas maximus). Am. J. Veterin. Res., 64, 109-114.
44. Ishizaki T., Sasaki T., Suganuma T., Horai Y., Chiba K., Watanabe M., Asuke W., Hoshi H. (1980): Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral. Eur. J. Clin. Pharmacol., 18, 407-414.
45. Aberg G., Ciofalo V.B., Pendleton R.G., et al. (1995): Inversion of (R)- to (S)-ketoprofen in eight animal species. Chirality, 7, 383-387.
46. Lees P., Taylor P.M., Landoni F.M., Arifah A.K., Waters C. (2003): Ketoprofen in the Cat: Pharmacodyn. Chiral Pharmacokinet. Veterin. J. 165, 21-35.